Author: admin

“Cholangiocarcinoma Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Cholangiocarcinoma pipeline constitutes 55+ key companies continuously working towards developing 60+ Cholangiocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Cholangiocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Cholangiocarcinoma Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cholangiocarcinoma Market.

Some of the key takeaways from the Cholangiocarcinoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Cholangiocarcinoma treatment therapies with a considerable amount of success over the years. 
• Cholangiocarcinoma companies working in the treatment market are Well Marker Bio, Sirnaomics, Kinnate Biopharma, Medivir, Eisai Co., Ltd., TransThera Biosciences, Hutchison Medipharma Limited, RedHill Biopharma Limited, Compass Therapeutics, Merck Sharp & Dohme, Eisai, Merck & Co, Zymeworks and BeiGene, Decalth Systems, Basilea Pharmaceutica, AstraZeneca, Taiho Oncology, and others, are developing therapies for the Cholangiocarcinoma treatment 

• Emerging Cholangiocarcinoma therapies in the different phases of clinical trials are- WM-S1, STP-705, KIN-3248, MIV-818, E7090, TT-00420, HMPL-453, ABC294640, CTX-009, KEYTRUDA (pembrolizumab), Tasurgratinib (E7090), LENVIMA (lenvatinib), Zanidatamab, Melphalan, Derazantinib, Imfinzi (durvalumab), TAS-120 (futibatinib), and others are expected to have a significant impact on the Cholangiocarcinoma market in the coming years.   
• In May 2023, Richard Kim discussed the investigation of RLY-4008 as a treatment for individuals diagnosed with cholangiocarcinoma possessing an FGFR2 fusion or rearrangement. RLY-4008, an exceptionally selective and irreversible FGFR2 inhibitor, is presently undergoing assessment in the phase 1/2 REFOCUS trial (NCT04526106). Initial data presented at the 2022 ESMO Congress revealed that among patients with FGFR inhibitor–naïve cholangiocarcinoma and an FGFR2 fusion or rearrangement (n = 17), there was an observed overall response rate of 88.2%.
• In April 2023, Nuvectis Pharma shared key findings from the poster presentation of NXP800 during the American Association for Cancer Research (“AACR”) Annual Meeting 2023 held in Orlando, FL. The strong preclinical efficacy displayed by NXP800 in cholangiocarcinoma patient-derived xenograft (PDX) models is seen as a promising sign for potential clinical advantages. Cholangiocarcinoma is notably challenging to treat, often resulting in unfavorable outcomes, and these recent findings offer hope for future treatment prospects for patients.
• In April 2023, Verismo Therapeutics has been granted fast-track designation by the US Food and Drug Administration (FDA) for its investigational new drug, SynKIR-110. SynKIR-110 is an experimental medication aimed at addressing severe diseases and life-threatening conditions, specifically targeting mesothelin-expressing mesothelioma, ovarian cancer, and cholangiocarcinoma.
• In January 2023, Taiho Oncology, Inc. has announced the publication of findings from the pivotal Phase 2 FOENIX*-CCA2 clinical trial of futibatinib in The New England Journal of Medicine (NEJM) on January 19, 2023. The trial demonstrated substantial clinical benefits of futibatinib in patients previously treated for FGFR2 fusion/rearrangement-positive intrahepatic cholangiocarcinoma (iCCA). The results revealed an objective response rate of 42% upon independent review, with a median response duration of 9.7 months. Futibatinib exhibited enduring responses and survival rates that exceeded historical chemotherapy data for previously treated iCCA patients.
• In October 2022, Invitae has formed a collaboration with AstraZeneca, leveraging Invitae’s Ciitizen natural history data for a comprehensive examination involving retrospective and prospective studies of individuals diagnosed with cholangiocarcinoma, a rare cancer affecting the bile duct. This partnership facilitates the exchange of meticulously curated, patient-consented data sourced from the Cholangiocarcinoma Foundation (CCF), a prominent patient advocacy group dedicated to discovering a cure and enhancing the lives of individuals impacted by cholangiocarcinoma.
• In November 2022, The FDA has awarded orphan drug designation for ZB131 in the treatment of cholangiocarcinoma, as confirmed by the drug’s manufacturer. ZB131, developed by ZielBio, is a monoclonal antibody that demonstrates high affinity and specificity for cancer-specific plectin.

Cholangiocarcinoma Overview

A type of cancer known as cholangiocarcinoma develops in the cells lining the bile duct, which serves as the liver’s drainage channel for bile. Bile duct cancer, another name for this rare type of cancer, usually affects adults over 50, however it can strike anyone at any age.

Get a Free Sample PDF Report to know more about Cholangiocarcinoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-pipeline-insight

Emerging Cholangiocarcinoma Drugs Under Different Phases of Clinical Development Include:

• WM-S1: Well Marker Bio
• STP-705: Sirnaomics
• KIN-3248: Kinnate Biopharma
• MIV-818: Medivir
• E7090: Eisai Co., Ltd.
• TT-00420: TransThera Biosciences
• HMPL-453: Hutchison Medipharma Limited
• ABC294640: RedHill Biopharma Limited
• CTX-009: Compass Therapeutics
• KEYTRUDA (pembrolizumab): Merck Sharp & Dohme
• Tasurgratinib (E7090): Eisai
• LENVIMA (lenvatinib): Eisai and Merck & Co
• Zanidatamab: Zymeworks and BeiGene
• Melphalan: Decalth Systems
• Derazantinib: Basilea Pharmaceutica
• Imfinzi (durvalumab): AstraZeneca
• TAS-120 (futibatinib): Taiho Oncology

Cholangiocarcinoma Route of Administration

Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Cholangiocarcinoma Molecule Type

Cholangiocarcinoma Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Cholangiocarcinoma Pipeline Therapeutics Assessment

• Cholangiocarcinoma Assessment by Product Type
• Cholangiocarcinoma By Stage and Product Type
• Cholangiocarcinoma Assessment by Route of Administration
• Cholangiocarcinoma By Stage and Route of Administration
• Cholangiocarcinoma Assessment by Molecule Type
• Cholangiocarcinoma by Stage and Molecule Type

DelveInsight’s Cholangiocarcinoma Report covers around 60+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Cholangiocarcinoma product details are provided in the report. Download the Cholangiocarcinoma pipeline report to learn more about the emerging Cholangiocarcinoma therapies

Some of the key companies in the Cholangiocarcinoma Therapeutics Market include:

Key companies developing therapies for Cholangiocarcinoma are –  Merck KGaA, Eisai Inc., Janssen Research & Development, LLC, 3D Medicines, Basilea Pharmaceutica, Hutchison Medipharma Limited, Jiangsu HengRui Medicine, TransThera Sciences, RedHill Biopharma, Eli Lilly and Company, Elevation oncology, Senhwa Biosciences, InnoCare Pharma, Genoscience Pharma, Intensity therapeutics, Elucida Oncology, GlaxoSmithKline, Verismo Therapeutics, Sirnaomics, Toray Industries, Inc, Kinnate Biopharma, Boehringer Ingelheim, Wellmarker Bio, Arbele Limited, NGM Biopharmaceuticals, Inc., Elicio Therapeutics, Xencor, Inc., Celon Pharma SA, and others.

Cholangiocarcinoma Pipeline Analysis:

The Cholangiocarcinoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Cholangiocarcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cholangiocarcinoma Treatment.
• Cholangiocarcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cholangiocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cholangiocarcinoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cholangiocarcinoma drugs and therapies

Cholangiocarcinoma Pipeline Market Drivers

• Increasing Incidence of Cholangiocarcinoma, increasing R&D Activities, increasing Awareness are some of the important factors that are fueling the Cholangiocarcinoma Market.

Cholangiocarcinoma Pipeline Market Barriers

• However, high cost of drugs, high Incidence of adverse events and other factors are creating obstacles in the Cholangiocarcinoma Market growth.

Scope of Cholangiocarcinoma Pipeline Drug Insight    

• Coverage: Global
• Key Cholangiocarcinoma Companies: Well Marker Bio, Sirnaomics, Kinnate Biopharma, Medivir, Eisai Co., Ltd., TransThera Biosciences, Hutchison Medipharma Limited, RedHill Biopharma Limited, Compass Therapeutics, Merck Sharp & Dohme, Eisai, Merck & Co, Zymeworks and BeiGene, Decalth Systems, Basilea Pharmaceutica, AstraZeneca, Taiho Oncology, and others
• Key Cholangiocarcinoma Therapies: WM-S1, STP-705, KIN-3248, MIV-818, E7090, TT-00420, HMPL-453, ABC294640, CTX-009, KEYTRUDA (pembrolizumab), Tasurgratinib (E7090), LENVIMA (lenvatinib), Zanidatamab, Melphalan, Derazantinib, Imfinzi (durvalumab), TAS-120 (futibatinib), and others
• Cholangiocarcinoma Therapeutic Assessment: Cholangiocarcinoma current marketed and Cholangiocarcinoma emerging therapies
• Cholangiocarcinoma Market Dynamics: Cholangiocarcinoma market drivers and Cholangiocarcinoma market barriers 

Request for Sample PDF Report for Cholangiocarcinoma Pipeline Assessment and clinical trials

Table of Contents

1. Cholangiocarcinoma Report Introduction

2. Cholangiocarcinoma Executive Summary

3. Cholangiocarcinoma Overview

4. Cholangiocarcinoma- Analytical Perspective In-depth Commercial Assessment

5. Cholangiocarcinoma Pipeline Therapeutics

6. Cholangiocarcinoma Late Stage Products (Phase II/III)

7. Cholangiocarcinoma Mid Stage Products (Phase II)

8. Cholangiocarcinoma Early Stage Products (Phase I)

9. Cholangiocarcinoma Preclinical Stage Products

10. Cholangiocarcinoma Therapeutics Assessment

11. Cholangiocarcinoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Cholangiocarcinoma Key Companies

14. Cholangiocarcinoma Key Products

15. Cholangiocarcinoma Unmet Needs

16 . Cholangiocarcinoma Market Drivers and Barriers

17. Cholangiocarcinoma Future Perspectives and Conclusion

18. Cholangiocarcinoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Insights into Cholangiocarcinoma Pipeline 2024: Latest Developments, FDA Approvals, Clinical Trials, and Therapeutic Innovations Unveiled by DelveInsight | Merck, Eisai, Janssen Research, 3D Medicines

“Bladder cancer Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Bladder cancer pipeline constitutes 100+ key companies continuously working towards developing 100+ Bladder cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Bladder cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Bladder cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bladder cancer Market.

Some of the key takeaways from the Bladder cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Bladder cancer treatment therapies with a considerable amount of success over the years. 
• Bladder cancer companies working in the treatment market are Ractigen Therapeutics, XNK Therapeutics, Vaxiion Therapeutics, Vyriad, Inc., Istari Oncology Inc., Theralase Technologies Inc., Taiho Oncology, Inc., Lepu Biopharma CO.,Ltd., Janssen Research & Development, LLC, Asieris Pharmaceuticals, ImmunityBio, CG Oncology, UroGen, G1 Therapeutics, BeiGene, and others, are developing therapies for the Bladder cancer treatment 

• Emerging Bladder cancer therapies in the different phases of clinical trials are- RAG-01, XNK03, VAX014, MV-NIS, Lerapolturev, TLD-1433, Futibatinib, HX-008, TAR-200, APL-1202, N-803, CG0070, UGN-102, Trilaciclib, Tislelizumab, and others are expected to have a significant impact on the Bladder cancer market in the coming years.   
• In July 2022, The FDA has acknowledged receipt of a Biologics License Application (BLA) submitted by ImmunityBio, Inc. (NASDAQ: IBRX), for its antibody cytokine fusion protein proposed as a therapy for patients diagnosed with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) accompanied by Ta or T1 disease or without. ImmunityBio, a prominent clinical-stage immunotherapy company, filed the BLA citing promising outcomes from various studies on the investigational treatment, including the ongoing QUILT 3.032 trial. The Prescription Drug User Fee Act (PDUFA) target action date is slated for May 23, 2023.
• In June 2022, CG Oncology disclosed preliminary findings from two ongoing clinical investigations to be showcased at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. The initial presentation focuses on efficacy and safety outcomes from a global Phase 2 study (CORE1) assessing CG0070 combined with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for treating patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG). The second presentation centers on a Phase 1b/2 study (CORE2) investigating CG0070 combined with OPDIVO® (nivolumab) as a neoadjuvant immunotherapy for Muscle-Invasive Bladder Cancer (MIBC) in cisplatin-ineligible patients.
• In July 2022, Nanostics Inc. initiated a prospective clinical research endeavor aimed at confirming the efficacy of ClarityDX Bladder, a pioneering and less invasive diagnostic test for bladder cancer. This study leverages Nanostics’ ClarityDX diagnostic platform and is conducted in collaboration with the University of Alberta’s Alberta Prostate Cancer Research Initiative (APCaRI) and DynaLIFE Medical Labs.
• In May 2022, Asieris Pharmaceuticals disclosed that the ANTICIPATE Study will be showcased at the 2022 American Society of Clinical Oncology (ASCO) annual meeting held from June 3-7, 2022, in Chicago. The study evaluates the administration of oral APL-1202 combined with BeiGene’s tislelizumab versus the sole use of tislelizumab as neoadjuvant therapy (NAC) in individuals diagnosed with muscle invasive bladder cancer (MIBC).
• In March 2022, Protara Therapeutics, Inc. declared the dosing of the initial patient in ADVANCED-1, a Phase 1 clinical study assessing TARA-002, an investigational cell-based immunopotentiator developed for treating non-muscle invasive bladder cancer (NMIBC).
• In January 2022, Vaxiion Therapeutics shared that the U.S. Food and Drug Administration (FDA) approved the company’s Investigational New Drug application (IND) for VAX014, allowing its investigative use for treating solid tumors resistant to conventional therapies through intralesional treatment. VAX014 represents a pioneering recombinant bacterial minicell-based oncolytic immunotherapy.

Bladder cancer Overview

The most prevalent tumor of the urinary tract is bladder cancer (BC). The bladder wall is composed of many layers. Different cell types make up each layer, and bladder cancer (BC) starts when normal bladder lining cells, most often urothelial cells, alter and proliferate uncontrollably to create masses known as tumors.

Get a Free Sample PDF Report to know more about Bladder cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/bladder-cancer-pipeline-insight

Emerging Bladder cancer Drugs Under Different Phases of Clinical Development Include:

• RAG-01: Ractigen Therapeutics
• XNK03: XNK Therapeutics
• VAX014: Vaxiion Therapeutics
• MV-NIS: Vyriad, Inc.
• Lerapolturev: Istari Oncology Inc.
• TLD-1433: Theralase Technologies Inc.
• Futibatinib: Taiho Oncology, Inc.
• HX-008: Lepu Biopharma CO.,Ltd.
• TAR-200: Janssen Research & Development, LLC
• APL-1202: Asieris Pharmaceuticals
• N-803: ImmunityBio
• CG0070: CG Oncology
• UGN-102: UroGen
• Trilaciclib: G1 Therapeutics
• Tislelizumab: BeiGene

Bladder cancer Route of Administration

Bladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Bladder cancer Molecule Type

Bladder cancer Products have been categorized under various Molecule types, such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Bladder cancer Pipeline Therapeutics Assessment

• Bladder cancer Assessment by Product Type
• Bladder cancer By Stage and Product Type
• Bladder cancer Assessment by Route of Administration
• Bladder cancer By Stage and Route of Administration
• Bladder cancer Assessment by Molecule Type
• Bladder cancer by Stage and Molecule Type

DelveInsight’s Bladder cancer Report covers around 100+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Bladder cancer product details are provided in the report. Download the Bladder cancer pipeline report to learn more about the emerging Bladder cancer therapies

Some of the key companies in the Bladder cancer Therapeutics Market include:

Key companies developing therapies for Bladder cancer are – Janssen Research & Development, LLC, Astellas Pharma, RemeGen Co., Ltd., UroGen Pharma Ltd., Flame Biosciences, Aura Biosciences, BeiGene, Incyte Corporation, CG Oncology, FKD Therapies, Bristol-Myers Squibb, LintonPharm Co., Ltd., ImmunityBio, Inc., Hamlet Pharma AB, Asieris Pharmaceuticals, Pfizer, Taizhou Hanzhong biomedical co. LTD, Protara Therapeutics, CicloMed LLC, enGene, Inc., Emtora Biosciences, Theralase Inc.,  Vaxiion Therapeutics, QED Therapeutics, G1 Therapeutics, AN0025, Kyowa Kirin, Inc., Infinity Pharmaceuticals, Shanghai Hengrui Pharmaceutical Co., Ltd., HiberCell, Inc., Ikena Oncology, Genentech, Fusion Pharmaceuticals, GI Innovation,SOTIO Biotech AG, Celon Pharma SA, 4D Pharma PLC, and others.

Bladder cancer Pipeline Analysis:

The Bladder cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Bladder cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bladder cancer Treatment.
• Bladder cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Bladder cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bladder cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Bladder cancer drugs and therapies

Bladder cancer Pipeline Market Drivers

• Increase in the number of patients suffering from non-muscle invasive bladder cancer, development of novel therapies and favorable government policies are some of the important factors that are fueling the Bladder cancer Market.

Bladder cancer Pipeline Market Barriers

• However, identifying the patient population with specific mutations for targeted therapy regimens, lack of awareness about the advanced cancer therapies and other factors are creating obstacles in the Bladder cancer Market growth.

Scope of Bladder cancer Pipeline Drug Insight    

• Coverage: Global
• Key Bladder cancer Companies: Ractigen Therapeutics, XNK Therapeutics, Vaxiion Therapeutics, Vyriad, Inc., Istari Oncology Inc., Theralase Technologies Inc., Taiho Oncology, Inc., Lepu Biopharma CO.,Ltd., Janssen Research & Development, LLC, Asieris Pharmaceuticals, ImmunityBio, CG Oncology, UroGen, G1 Therapeutics, BeiGene, and others
• Key Bladder cancer Therapies: RAG-01, XNK03, VAX014, MV-NIS, Lerapolturev, TLD-1433, Futibatinib, HX-008, TAR-200, APL-1202, N-803, CG0070, UGN-102, Trilaciclib, Tislelizumab, and others
• Bladder cancer Therapeutic Assessment: Bladder cancer current marketed and Bladder cancer emerging therapies
• Bladder cancer Market Dynamics: Bladder cancer market drivers and Bladder cancer market barriers 

Request for Sample PDF Report for Bladder cancer Pipeline Assessment and clinical trials

Table of Contents

1. Bladder cancer Report Introduction

2. Bladder cancer Executive Summary

3. Bladder cancer Overview

4. Bladder cancer- Analytical Perspective In-depth Commercial Assessment

5. Bladder cancer Pipeline Therapeutics

6. Bladder cancer Late Stage Products (Phase II/III)

7. Bladder cancer Mid Stage Products (Phase II)

8. Bladder cancer Early Stage Products (Phase I)

9. Bladder cancer Preclinical Stage Products

10. Bladder cancer Therapeutics Assessment

11. Bladder cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Bladder cancer Key Companies

14. Bladder cancer Key Products

15. Bladder cancer Unmet Needs

16 . Bladder cancer Market Drivers and Barriers

17. Bladder cancer Future Perspectives and Conclusion

18. Bladder cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bladder cancer Pipeline Assessment 2024: FDA Approvals, Clinical Trials, Therapies and Companies by DelveInsight | Aura Biosciences, BeiGene, Incyte, CG Oncology, FKD Therapies

“Ischemic Stroke Pipeline”

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Ischemic Stroke pipeline constitutes 50+ key companies continuously working towards developing 55+ Ischemic Stroke treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Ischemic Stroke Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Ischemic Stroke Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ischemic Stroke Market.

Some of the key takeaways from the Ischemic Stroke Pipeline Report:

• Companies across the globe are diligently working toward developing novel Ischemic Stroke treatment therapies with a considerable amount of success over the years. 
• Ischemic Stroke companies working in the treatment market are TargED Biopharmaceuticals, Saillant Therapeutics, AbbVie, Revalesio Corporation, Biogen, Acticor Biotech, ZZ Biotech, GNT Pharma, Athersys, Inc., Acticor Biotech, Lumosa Therapeutics, Avilex Pharma, and others, are developing therapies for the Ischemic Stroke treatment 

• Emerging Ischemic Stroke therapies in the different phases of clinical trials are- Microlyse, ST-01, Elezanumab, RNS60, BIIB131, Glenzocimab, 3K3A-APC, Nelonemdaz, MultiStem, Glenzocimab, LT3001, AVLX-144, and others are expected to have a significant impact on the Ischemic Stroke market in the coming years.   
• In July 2022, ACTICOR BIOTECH disclosed that its drug candidate, glenzocimab, obtained “PRIority Medicines” designation from the European Medicines Agency (EMA) for treating stroke patients. This designation facilitates Acticor Biotech in enhancing engagements and securing preliminary discussions with regulatory bodies to solidify the clinical development strategy for glenzocimab in stroke treatment.
• In July 2022, NervGen Pharma revealed that a groundbreaking preclinical study conducted by the University of Cincinnati and Case Western Reserve University (CWRU) has been published in the scientific journal Cell Reports. This study showcases the effectiveness of NervGen’s unique drug, NVG-291-R, in facilitating nervous system repair and notable functional recuperation in a mouse model of severe ischemic stroke. Notably, the treatment demonstrated significant recovery benefits even when initiated up to 7 days after the onset of the stroke.
• In June 2022, Pharmazz Inc has unveiled encouraging top-line outcomes from its Phase III clinical trial assessing sovateltide’s efficacy in treating acute ischemic stroke. The results highlighted a notable increase, at the 90-day mark, in the number of participants showing a significant improvement of 2 points or more on the modified Rankin Score (mRS), a substantial reduction in the median score on the mRS, and a considerable decrease in the number of individuals displaying an improvement of 6 or more points on the NIHSS Level of Consciousness (1A)
• In February 2022, Acticor Biotech disclosed encouraging results derived from its Phase Ib/IIa ACTIMIS clinical trial evaluating glenzocimab as an adjunctive therapy alongside the standard care for acute ischemic stroke (AIS) patients. The findings indicated the trial successfully achieved its primary objective by confirming the favorable safety profile of glenzocimab.
• In February 2022, Bayer revealed that the U.S. Food and Drug Administration (FDA) has provided Fast Track Designation for its experimental drug asundexian (BAY2433334) concerning its potential application as a treatment for secondary prevention among patients who have experienced a non-cardioembolic ischemic stroke.
• In May 2022, Athersys, Inc. disclosed that its collaborator, HEALIOS K.K. (Healios), released the key findings from its Japan-based ischemic stroke study, TREASURE. The study revealed notable improvements in predetermined functional measures associated with “independence” and positive outcomes such as mRS ≤2, Barthel Index ≥95, and Global Recovery linked to MultiStem treatment. However, the primary endpoint of achieving an excellent outcome at 90 days did not demonstrate statistical significance in the overall population. Importantly, there were no substantial differences observed in safety outcomes, including mortality and life-threatening adverse events, between the treatment and placebo groups.

Ischemic Stroke Overview

An ischemic stroke, also known as a brain attack, happens when a blood artery in the brain breaks or when something stops the blood supply to a portion of the brain. Either way, certain brain regions suffer harm or even die. A stroke can result in death, long-term incapacity, or permanent brain damage.

Get a Free Sample PDF Report to know more about Ischemic Stroke Pipeline Therapeutic Assessment – https://www.delveinsight.com/report-store/ischemic-stroke-pipeline-insight

Emerging Ischemic Stroke Drugs Under Different Phases of Clinical Development Include:

• Microlyse: TargED Biopharmaceuticals
• ST-01: Saillant Therapeutics
• Elezanumab: AbbVie
• RNS60: Revalesio Corporation
• BIIB131: Biogen
• Glenzocimab: Acticor Biotech
• 3K3A-APC: ZZ Biotech
• Nelonemdaz: GNT Pharma
• MultiStem: Athersys, Inc.
• Glenzocimab: Acticor Biotech
• Elezanumab: AbbVie
• LT3001: Lumosa Therapeutics
• AVLX-144: Avilex Pharma

Ischemic Stroke Route of Administration

Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Ischemic Stroke Molecule Type

Ischemic Stroke Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Ischemic Stroke Pipeline Therapeutics Assessment

• Ischemic Stroke Assessment by Product Type
• Ischemic Stroke By Stage and Product Type
• Ischemic Stroke Assessment by Route of Administration
• Ischemic Stroke By Stage and Route of Administration
• Ischemic Stroke Assessment by Molecule Type
• Ischemic Stroke by Stage and Molecule Type

DelveInsight’s Ischemic Stroke Report covers around 55+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Ischemic Stroke product details are provided in the report. Download the Ischemic Stroke pipeline report to learn more about the emerging Ischemic Stroke therapies

Some of the key companies in the Ischemic Stroke Therapeutics Market include:

Key companies developing therapies for Ischemic Stroke are – Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharmaceutical Co., Ltd., Genentech, Inc., NoNO Inc., Pharming Technologies B.V., Biogen, Athersys, Inc., Tarveda Therapeutics, Nanjing Yoko Biomedical Co., Ltd., TrueBinding, Inc., GNT Pharma, Roche, DiaMedica Therapeutics Inc, aptaTargets, Avilex Pharma, Lumosa Therapeutics, NC Medial Research Inc, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals, SanBio, ZZ Biotech, Revalesio, Stemedica Cell Technologies, StemCyte, Ninnion, Algernon Pharmaceuticals, Primary Peptides, TMS, Tasly Pharmaceutical, Pharmazz and others.

Ischemic Stroke Pipeline Analysis:

The Ischemic Stroke pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Ischemic Stroke with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ischemic Stroke Treatment.
• Ischemic Stroke key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Ischemic Stroke Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ischemic Stroke market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Ischemic Stroke drugs and therapies

Ischemic Stroke Pipeline Market Drivers

• Rising incidence of Acute Ischemic Stroke, increasing prevalence of lifestyle associated disorders such as diabetes and hypertension, rising geriatric population are some of the important factors that are fueling the Ischemic Stroke Market.

Ischemic Stroke Pipeline Market Barriers

• However, challenges associated with the clinical research, challenges with the diagnosis of AIS and other factors are creating obstacles in the Ischemic Stroke Market growth.

Scope of Ischemic Stroke Pipeline Drug Insight    

• Coverage: Global
• Key Ischemic Stroke Companies: TargED Biopharmaceuticals, Saillant Therapeutics, AbbVie, Revalesio Corporation, Biogen, Acticor Biotech, ZZ Biotech, GNT Pharma, Athersys, Inc., Acticor Biotech, Lumosa Therapeutics, Avilex Pharma, and others
• Key Ischemic Stroke Therapies: Microlyse, ST-01, Elezanumab, RNS60, BIIB131, Glenzocimab, 3K3A-APC, Nelonemdaz, MultiStem, Glenzocimab, LT3001, AVLX-144, and others
• Ischemic Stroke Therapeutic Assessment: Ischemic Stroke current marketed and Ischemic Stroke emerging therapies
• Ischemic Stroke Market Dynamics: Ischemic Stroke market drivers and Ischemic Stroke market barriers 

Request for Sample PDF Report for Ischemic Stroke Pipeline Assessment and clinical trials

Table of Contents

1. Ischemic Stroke Report Introduction

2. Ischemic Stroke Executive Summary

3. Ischemic Stroke Overview

4. Ischemic Stroke- Analytical Perspective In-depth Commercial Assessment

5. Ischemic Stroke Pipeline Therapeutics

6. Ischemic Stroke Late Stage Products (Phase II/III)

7. Ischemic Stroke Mid Stage Products (Phase II)

8. Ischemic Stroke Early Stage Products (Phase I)

9. Ischemic Stroke Preclinical Stage Products

10. Ischemic Stroke Therapeutics Assessment

11. Ischemic Stroke Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Ischemic Stroke Key Companies

14. Ischemic Stroke Key Products

15. Ischemic Stroke Unmet Needs

16 . Ischemic Stroke Market Drivers and Barriers

17. Ischemic Stroke Future Perspectives and Conclusion

18. Ischemic Stroke Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ischemic Stroke Pipeline Analysis, 2024 Updates: Companies, Treatment, FDA, EMA, and PMDA Approvals | Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharma, Genentech, Biogen, Athersys, Tarveda